Apatinib as an alternative therapy for advanced hepatocellular carcinoma

被引：0
|
作者：
Xi-Hao Zhang [1 ,2 ]
Man-Qing Cao [2 ,3 ]
Xiu-Xiu Li [1 ,2 ,4 ]
Ti Zhang [1 ,2 ,5 ]
机构：
[1] Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer
[2] Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University
[3] Department of Breast Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer
[4] Digestive Department, Shanxi Province Tumor Hospital
[5] Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital
来源：
World Journal of Hepatology | 2020年 / 12卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R735.7 [肝肿瘤];
学科分类号：
100214 ;
摘要：
Angiogenesis plays an important role in the occurrence and development of tumors. Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis. Apatinib, a tyrosine kinase inhibitor, can specifically inhibit vascular endothelial growth factor receptor 2, showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma(HCC). This article intends to review the clinical research and application prospects of apatinib in the field of HCC.
引用
收藏
页码：766 / 774
页数：9
相关论文
共 50 条
  • [1] Apatinib as an alternative therapy for advanced hepatocellular carcinoma
    Zhang, Xi-Hao
    Cao, Man-Qing
    Li, Xiu-Xiu
    Zhang, Ti
    WORLD JOURNAL OF HEPATOLOGY, 2020, 12 (10) : 766 - 774
  • [2] Apatinib is effective for treatment of advanced hepatocellular carcinoma
    Kong, Yinlong
    Sun, Lin
    Hou, Zhenyu
    Zhang, Yongqiang
    Chen, Ping
    Cui, Yunlong
    Zhu, Xiaolin
    Song, Tianqiang
    Li, Qiang
    Li, Huikai
    Zhang, Ti
    Qin, Lunxiu
    ONCOTARGET, 2017, 8 (62): : 105596 - 105605
  • [3] Efficacy of camrelizumab and apatinib combination therapy versus apatinib only in treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Swed, Sarya
    Motawea, Karam R.
    AbdelQadir, Yossef Hassan
    Gamal, Mohamed
    El-Sakka, Amro A.
    Kandil, Omneya A.
    Abdelazeem, Basel
    Abdelaziz, Muhammad
    Wahsh, Engy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16147 - E16147
  • [4] Apatinib for hepatocellular carcinoma
    Ni, Yang
    Ye, Xin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (04) : 741 - 742
  • [5] Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study
    He, Wei
    Liao, Leen
    Hu, Dandan
    Li, Binkui
    Wang, Chenwei
    Qiu, Jiliang
    Liao, Yadi
    Liu, Wenwu
    Yang, Zhiwen
    Zhang, Yuanping
    Yuan, Yichuan
    Li, Kai
    Yuan, Yunfei
    Zheng, Yun
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (16)
  • [6] Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma
    Zhu, Yuxia
    Feng, Bo
    Mei, Lin
    Sun, Ruiqing
    Guo, Changcun
    Zhu, Jiangyi
    JOURNAL OF BUON, 2019, 24 (02): : 608 - 614
  • [7] Therapy in Advanced Hepatocellular Carcinoma
    Javan, Hanna
    Dayyani, Farshid
    Abi-Jaoudeh, Nadine
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2020, 37 (05) : 466 - 474
  • [8] Thalidomide for advanced hepatocellular carcinoma - Is this a real alternative?
    Wadler, S
    CANCER, 2005, 103 (01) : 1 - 4
  • [9] Efficacy and safety of low-dose apatinib in advanced hepatocellular carcinoma.
    Meng, Lingbin
    Zheng, Zhuangzhuang
    Ji, Rui
    Xu, Xiaochun
    Xin, Ying
    Jiang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
    Chen, Lei
    Sun, Tao
    Wu, Linxia
    Zhang, Weihua
    Ren, Yanqiao
    Xiang, Dongqiao
    Liang, Bin
    Zheng, Chuansheng
    JOURNAL OF ONCOLOGY, 2021, 2021
12345